Key points are not available for this paper at this time.
variants with altered susceptibilities to inhibition, triage-nonspecific, or off-target molecules and validate bona fide inhibitors, with the most potent thus far being the first-in-class drug nirmatrelvir.
Moghadasi et al. (Tue,) studied this question.